Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Boston, Massachusetts
- Most recent report
- 10-Q, filed Aug 5, 2026
- Incorporated
- Delaware
- Filings on record
- 220 filings
- On EDGAR
- CIK 2012593
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company Emerging growth company
Financials 8 of 9
News 8 of 21
Prospectuses and Registrations 8 of 12
- S-3ASR Automatic shelf registration Mar 10, 2026
- S-8 Registration statement for an employee plan Mar 10, 2026
- 424B5 Prospectus supplement for an offering Jan 7, 2026
- 424B5 Prospectus supplement for an offering Sep 10, 2025
- 424B5 Prospectus supplement for an offering Sep 8, 2025
- S-3 Shelf registration statement Jul 1, 2025
- S-3 Shelf registration statement Jul 1, 2025
- S-8 Registration statement for an employee plan Mar 11, 2025
Proxies 4
Ownership 8 of 150
- 144 Notice of a proposed sale of restricted stock Aug 19, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 14, 2026
- 4 Insider reported a trade Aug 12, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 12, 2026
- 4 Insider reported a trade Jul 29, 2026
- 4 Insider reported a trade Jul 15, 2026
- 4 Insider reported a trade Jul 1, 2026
Other 8 of 24
- ARS Annual report sent to shareholders Apr 23, 2026
- EFFECT Notice that a registration became effective Jul 9, 2025
- EFFECT Notice that a registration became effective Jul 9, 2025
- CORRESP Reply to SEC staff Jul 7, 2025
- CORRESP Reply to SEC staff Jul 7, 2025
- UPLOAD Comment letter from SEC staff Jul 7, 2025
- UPLOAD Comment letter from SEC staff Jul 7, 2025
- ARS Annual report sent to shareholders Apr 24, 2025
Everything here comes from Rapport Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.